Ligand triggers of classical preconditioning and postconditioning

Area of Science:

• Cardiovascular Pharmacology
• Molecular Cardiology
• Translational Medicine

Background:

• Ischemic preconditioning (IPC) and postconditioning (PC) are potent endogenous mechanisms protecting the heart against ischemia-reperfusion injury.
• These protective effects are known to be mediated by specific receptor signaling pathways.

Purpose of the Study:

• To review the major ligand classes and their receptors involved in IPC and PC-induced cardioprotection.
• To summarize the therapeutic window for each ligand class, particularly their efficacy when administered around reperfusion.
• To discuss receptor cross-talk and common signaling pathways.

Main Methods:

• Literature review focusing on studies assessing infarct size reduction as the primary endpoint for IPC and PC efficacy.
• Analysis of studies investigating specific ligand classes: adenosine, bradykinin, opioids, erythropoietin, adrenergics, and muscarinics.
• Inclusion of studies using myocardial stunning as an endpoint only when infarct size assessment was not feasible.

Main Results:

• Identified key ligands (adenosine, bradykinin, opioids, erythropoietin, adrenergics, muscarinics) and their associated receptors mediating cardioprotection.
• Summarized the timing of administration for optimal cardioprotective effects, highlighting ligands effective near reperfusion.
• Discussed the role of receptor cross-talk and shared intracellular signaling cascades.

Conclusions:

• Receptor-mediated pathways are central to the cardioprotective effects of IPC and PC.
• Understanding the specific ligands and their therapeutic windows is crucial for developing pharmacological strategies to enhance cardiac protection.
• Further research into receptor cross-talk may reveal novel therapeutic targets for preventing myocardial infarction.